tarextumab
mAbexperimental
Tarextumab is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01277146)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
NOTCH2 inhibitor
NOTCH3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTarextumab ↗
- ChEMBLCHEMBL3301588 ↗
Also known as
- omp-59r5
- omp-59r5
- omp-59r5
- tarextumab
- tarextumab
- tarextumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01859741 | Phase 1/Phase 2 (Phase 2) | May 1, 2013 | Mereo BioPharma |
| NCT01647828 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2012 | Cornell University, Mereo BioPharma |
| NCT01277146 | Phase 1 | Dec 1, 2010 | Mereo BioPharma, South Texas Accelerated Research Therapeutics, University of Michigan |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mereo BioPharma | For profit | 3 | 3 | 2 | 2010 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| South Texas Accelerated Research Therapeutics | For profit | 1 | 0 | 1 | 2010 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2010 |
4 organizations
Page 1 / 1